Blockade of glucagon signaling prevents or reverses diabetes onset only if residual β-cells persist
Glucagon secretion dysregulation in diabetes fosters hyperglycemia. Recent studies report that mice lacking glucagon receptor (Gcgr-/-) do not develop diabetes following streptozotocin (STZ)-mediated ablation of insulin-producing β-cells. Here, we show that diabetes prevention in STZ-treated Gcgr-/-...
Main Authors: | Nicolas Damond, Fabrizio Thorel, Julie S Moyers, Maureen J Charron, Patricia M Vuguin, Alvin C Powers, Pedro L Herrera |
---|---|
Format: | Article |
Language: | English |
Published: |
eLife Sciences Publications Ltd
2016-04-01
|
Series: | eLife |
Subjects: | |
Online Access: | https://elifesciences.org/articles/13828 |
Similar Items
-
Partners for life
by: Lena Eliasson, et al.
Published: (2016-05-01) -
Stathmin-2 Mediates Glucagon Secretion From Pancreatic α-Cells
by: Farzad Asadi, et al.
Published: (2020-02-01) -
Role of Glucagon and Its Receptor in the Pathogenesis of Diabetes
by: Yunbo Jia, et al.
Published: (2022-06-01) -
Glucagon and Its Receptors in the Mammalian Heart
by: Joachim Neumann, et al.
Published: (2023-08-01) -
New uses and formulations of glucagon for hypoglycaemia
by: Pilar I Beato-Víbora, et al.
Published: (2019-07-01)